Fundraising Fox

Sherlock Biosciences

Cambridge, US · Founded 2018 · Delaware corporation · 432 employees on LinkedIn · 8 known investors

Find your way into Sherlock Biosciences

636 people in our graph share verified history with the Sherlock Biosciences team — schools, employers, funds. One of them is your warm intro.

Nicole Gaudelliunlockedknows David R. Walt · together at Harvard University (overlapped)
knows the team · via Harvard University
×4knows the team · via Harvard Medical School
×4knows the team · via Brigham and Women's Hospital
×2knows the team · via Stony Brook University
Healthtech

Founders & leadership

Sherlock Biosciences was founded in 2018 by Rahul Dhanda, James Collins, and David Walt.

RD
Rahul DhandaCo-founder
JCJames Collins
James CollinsCo-founderVenture Partner at Catalio Capital Management, LP
DW
David WaltinCo-Founder and Director2017–2024Advisor at Illumina Ventures

Board

IRIssi Rozen
Issi RozeninMember Board of Directors2019–2022Investor at GV (Google Ventures)

Investors · 8

Catalio Capital Management, LPNew York
Illumina VenturesFoster City
Catalio Capital Managementreported · 2 sourcesNew York
Good Venturesreported · 2 sources
GV (Google Ventures)reportedMountain View · $250K – $50Mvia Issi Rozen · board
Northpond Venturesreported · 2 sourcesBethesda · $100K – $5M
Novalis LifeSciencesreported · 2 sourcesPortsmouth

Also in the syndicate · 1

Albany Capital

Reported raises · per SEC filings

Form D private placements

$112.8M disclosed across 2 rounds · 2019–2022

▶$80MraisedMar 2022 · 13 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael RubinDirector
  • Issi RozenDirector
  • David WaltDirector
  • James CollinsDirector
  • Bryan DechairoExecutive Officer, Director
Offering amount
$80M
Amount sold
$80M
First sale
Feb 2022
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$32.8MraisedApr 2019 · 10 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Rahul DhandaExecutive Officer, Director
  • James CollinsDirector
  • Issi RozenDirector
  • David WaltDirector
Offering amount
$33.8M
Amount sold
$32.8M
First sale
Apr 2019
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

3 people who came through Sherlock Biosciences went on to found or lead other companies.

David R. WaltDirectorFounded Protillion Biosciences +3Issi RozenDirectorFounded Verve TherapeuticsRahul DhandaCo-founder, CEO & President at Sherlock BiosciencesFounded Syntis Bio

Competitors · 1

by search overlap
Danaher3 shared keywordsDanaher is a global science and technology company specializing in biotech, diagnostics, and life sciences with businesses that innovate in drug development, molecular diagnostics, genomic medicine, and bioprocessing to help advance human health. Operating through multiple strategic platforms and with nearly 63,000 employees, Danaher develops technologies and solutions for researchers, biopharmaceutical producers, and healthcare systems globally.

Companies competing with Sherlock Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
Department of Agriculture (USDA)Phase I2023$175K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Sherlock Biosciences raises $80M Series B for at-home diagnostics - MassDevicemassdevice.com · Mar 2022Sherlock Bio raises $80 million to apply COVID-testing tech to other diseases - The Boston Globebostonglobe.com · Mar 2022Sherlock Bio raises $80 million to develop CRISPR-based diagnostics | Reutersreuters.com · Mar 2022Sherlock Biosciences unearths $80M to bring CRISPR-based tests into the home | Fierce Biotechfiercebiotech.com · Mar 2022Sherlock Biosciences Raises $80M in Series B Funding - FinSMEsfinsmes.com · Mar 2022Sherlock Biosciences Raises $80 Million in Series B Financing to Democratize At-Home Diagnostic Testingprnewswire.com · Mar 2022

Frequently asked questions

Who founded Sherlock Biosciences?
Sherlock Biosciences was founded by Rahul Dhanda, James Collins, David Walt in 2018.
Who are Sherlock Biosciences's investors?
Sherlock Biosciences's investors include Catalio Capital Management, LP, Illumina Ventures, Catalio Capital Management, Good Ventures, GV (Google Ventures), Northpond Ventures, Novalis LifeSciences.
How much funding has Sherlock Biosciences raised?
Sherlock Biosciences has disclosed $112.8M raised across 2 rounds.
Where is Sherlock Biosciences headquartered?
Sherlock Biosciences is headquartered in Cambridge, US.